Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants ...

29 August 2026 · By · Wire by Fusion42

Published

29 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

South Korea

◆ Source

Read at medicalxpress.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

The SINGLE-AF trial demonstrated that oral anticoagulants reduce the risk of stroke and major adverse events in patients with atrial fibrillation at intermediate risk of stroke, supporting expansion of their use beyond high-risk groups.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Patients at intermediate stroke risk with atrial fibrillation now have proven benefit from anticoagulants, opening a new market for Medtech and digital health founders targeting stroke prevention and patient management in this group.

◆ Coverage

1 source · 29 Aug 2026

◆ Related on Wire

◆ Topics

Medtechatrial-fibrillationstroke-preventionoral-anticoagulantsclinical-trialmedtech